Meeting
2016 Genitourinary Cancers Symposium
T-cell receptor (TCR) repertoire in metastatic renal cell carcinoma (RCC) patients treated with first-line vascular endothelial growth factor receptor blockade.
Authors
Thai Huu Ho
Mayo Clinic, Scottsdale, AZ
Thai Huu Ho , Robert Charles Gagnon , Yuan Liu , F. Stephen Hodi , Sabina Signoretti , Toni K. Choueiri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT00334282
Citation
J Clin Oncol 34, 2016 (suppl 2S; abstr 501)
DOI
10.1200/jco.2016.34.2_suppl.501
Abstract #
501
Poster Bd #
D6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC).
First Author: Matthew Scott Ernst
Poster
2020 ASCO Virtual Scientific Program
Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.
First Author: Shaan Dudani
Poster
2020 Genitourinary Cancers Symposium
Clinical outcomes of metastatic renal carcinoma following disease progression to programmed death (PD)-1 or PD-L1 inhibitors (I-O): A Meet-URO group real-world study (Meet-Uro 7).
First Author: Daniele Santini
Poster
2013 Genitourinary Cancers Symposium
Effect of VEGF and VEGFR polymorphisms on clinical outcome and response in patients with advanced renal cell carcinoma receiving first-line treatment.
First Author: Maristella Bianconi